ClinicalTrials.gg
Not yet recruitingNCT07598903Numaplus_FAUpdated May 22, 2026

Pharmacy-based Opportunistic Atrial Fibrillation Screening Integrated With Emergency Services (NUMAPLUS-FA)

An interventional study of Integrated pharmacy-based AF screening circuit in Atrial Fibrillation (Prevention of Stroke), Arrythmia, Cardiac and Mass Screening, sponsored by Centro de Emergencias Sanitarias 061 Andalucía. Not yet recruiting at 1 site in Spain. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by Centro de Emergencias Sanitarias 061 Andalucía · Not applicable, Interventional, and Screening

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
380
Allocation
Not applicable
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 247 studies in Atrial Fibrillation with a site in Spain — 53 open to participants now, 76 under way, 3 of them phase 3. Atrial Fibrillation · Spain.

Planned enrollment
74th of 162
380 · median 304
Started
2026
with 9 others
No phase
88 of 247
31 open now
Primary completion
2026-12
later than 32 of 75 live
Registered
244th of 247
by date

Among the 247 studies in Atrial Fibrillation with a site in Spain, this one is the 74th largest by planned enrollment of the 162 interventional ones that give a count, is one of 10 that started in 2026, is one of 88 with no phase, reaches primary completion later than 32 of the 75 other live ones, and was the 244th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

53 of the 247 studies in Atrial Fibrillation with a site in Spain are open now. Recruiting first, the newest first:

48 more — sign in →

All 53 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 247 studies in Atrial Fibrillation with a site in Spain, or all of them as a file.
02

Study summary

This study evaluates the feasibility and fidelity of an opportunistic atrial fibrillation (AF) screening programme conducted in 38 community pharmacies in Seville (Spain), using the Kardias® 6-lead portable ECG device, coordinated with the emergency medical services centre Salud Responde (CES 061) and primary care physicians. Eligible participants are individuals aged 65 years or older without a prior AF diagnosis who attend a participating pharmacy for any routine purpose. The screening consists of a 30-second ECG recording performed by a trained community pharmacist. Positive or indeterminate results are transmitted in real time to Salud Responde for clinical validation and referral to primary care. The study is evaluated using the RE-AIM framework (Reach, Effectiveness, Adoption, Implementation, Maintenance). The primary outcome is protocol fidelity, measured by the Implementation Adherence Grade (IAG). The study is part of the NUMAPLUS project, funded by INTERREG VI-A España-Portugal (POCTEP 2021-2027), co-financed by the European Regional Development Fund (ERDF).

Read the detailed description

STUDY DESIGN This is a prospective, single-cohort, type-1 effectiveness-implementation hybrid study conducted within the NUMAPLUS project (INTERREG VI-A España-Portugal, POCTEP 2021-2027, co-financed by the European Regional Development Fund). This design was selected because external evidence on the diagnostic accuracy of the Kardias® device is sufficient to justify its deployment, while uncertainty persists regarding the organisational conditions, care pathways and economic incentives required for its sustainable integration into the Andalusian community pharmacy network. The primary focus is on implementation outcomes; clinical outcomes related to atrial fibrillation screening are collected as secondary endpoints. The study is reported in accordance with the Standards for Reporting Implementation Studies (StaRI) guideline.

SETTING The study is conducted in 38 community pharmacies in the province of Seville affiliated with the Real e Ilustre Colegio Oficial de Farmacéuticos de Sevilla (RICOFS), selected by voluntary participation following an open invitation. Eligibility criteria for pharmacies required stable internet connectivity for access to the Numaplus application, completion of pre-study training, and absence of concurrent participation in another cardiovascular screening programme. Priority was given to pharmacies with 24-hour or 12-hour opening schedules. Geographic coverage targets at least three urban health zones per province and at least one semi-urban or rural zone per healthcare management area.

The study articulates three coordination levels: (1) the community pharmacy as the point of patient recruitment and screening; (2) Salud Responde (CES 061) as the clinical validation, risk stratification and real-time coordination node; and (3) the primary care physician as the responsible party for definitive diagnosis and initiation of treatment.

TRAINING OF PARTICIPATING PHARMACISTS Prior to the recruitment period, all enrolled pharmacists completed a structured training programme accredited by the Escuela Andaluza de Salud Pública (EASP) and the Agencia de Calidad Sanitaria de Andalucía (ACSA). The programme was delivered entirely online in asynchronous modality between 23 March and 13 April 2026 (10 hours total) through the EASP Moodle platform. It comprised four learning units: (1) epidemiological basis and scientific rationale for opportunistic AF screening; (2) detection protocol, radial pulse palpation technique, and interpretation of Kardias® device outputs; (3) data entry in the Numaplus platform, risk classification and patient communication within the pharmacy-Salud Responde circuit; and (4) ethical and legal framework, informed consent procedures, and data protection requirements. Certification required completion of all practical activities and a minimum score of 7 out of 10 on the final knowledge assessment.

INTERVENTION

The screening protocol comprises five sequential operational phases aligned with the RE-AIM framework:

Phase 1 (Reach): Opportunistic invitation during dispensing or consultation, without prior appointment. The pharmacist records the monthly denominator of unique patients aged 65 years or older using pharmacy management software. Reasons for refusal are recorded anonymously.

Phase 2 (Adoption): Following written informed consent, the case is opened in the Numaplus application. The pharmacist records current symptoms (palpitations, chest pain, dyspnoea, syncope), oral anticoagulant therapy status, and the CHA₂DS₂-VA score (0-6), adopted per the 2024 ESC Guidelines for AF Management in replacement of CHA₂DS₂-VASc.

Phase 3 (Implementation): The Kardias® 6-lead portable device is applied for a 30-second ECG recording (maximum 3 attempts). The device algorithm classifies the result as: Suspected AF / Sinus rhythm / Bradycardia / Tachycardia / Unclassified. Protocol fidelity is operationalised through the Implementation Adherence Grade (IAG). A performance-based financial incentive of 20 euros per complete and valid case is applied.

Phase 4 (Effectiveness): In case of suspected or indeterminate AF, the Numaplus platform automatically transmits a PDF containing the ECG tracing and clinical data to Salud Responde; simultaneously, the pharmacist places a direct call. The Salud Responde nurse applies a structured triage protocol: emergency 061 activation (heart rate >110 or \<60 bpm or alarm symptoms), medium priority referral (haemodynamically stable suspected AF, primary care appointment within 72 hours), or low priority referral (unclassified tracing, scheduled ECG at primary care). Definitive AF diagnosis is confirmed by the primary care physician.

Phase 5 (Maintenance): Six-month telephone follow-up conducted by Salud Responde, assessing anticoagulation initiation and adherence, health-related quality of life (visual analogue scale 0-10), and major adverse events (ischaemic stroke, major bleeding, death).

STATISTICAL ANALYSIS The primary analysis is precision-based, targeting 385 participants (operational target: 380, 10 per pharmacy). Categorical variables are reported as proportions with 95% confidence intervals (Clopper-Pearson); the IAG is estimated with an exact binomial 95% CI. Factors associated with low fidelity are explored by logistic regression. Missing data are handled by multiple imputation (MICE, 20 imputations) if below 15% under the MAR assumption. All analyses are conducted in R version 4.3 or higher.

03

Conditions studied

  • Atrial Fibrillation (Prevention of Stroke)
  • Arrythmia, Cardiac
  • Mass Screening
  • Pharmacies

Keywords

  • atrial fibrillation
  • opportunistic screening
  • community pharmacy
  • RE-AIM
  • implementation science
  • emergency medical services
  • portable ECG
  • hybrid implementation study
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 65 years or older
  2. Attending a participating community pharmacy for any routine healthcare purpose
  3. No prior documented or patient-reported diagnosis of atrial fibrillation
  4. Capacity to provide written

Exclusion criteria

Exclusion Criteria:

  1. Confirmed prior diagnosis of atrial fibrillation
  2. Implanted pacemaker, implantable cardioverter-defibrillator (ICD) or other intracardiac device
  3. Clinically evident haemodynamic instability requiring direct emergency 061 activation (active chest pain, severe dyspnoea, syncope)
  4. Concurrent participation in another cardiac rhythm monitoring study
  5. Inability to maintain the required position for a 30-second recording
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
380 participants (estimated)

Study arms

  • Experimental
    Pharmacy-based AF screening cohort

    Adults aged 65 years or older attending participating community pharmacies in Seville without prior diagnosis of atrial fibrillation, recruited opportunistically during routine pharmacy visits.

    Other: Integrated pharmacy-based AF screening circuit

Interventions

  • OtherIntegrated pharmacy-based AF screening circuit

    A coordinated opportunistic screening model integrating community pharmacies, emergency medical services (Salud Responde, CES 061) and primary care physicians. The model comprises: opportunistic patient identification during routine pharmacy visits; 30-second ECG recording using the Kardias 6-lead portable device; real-time data transmission via the Numaplus platform; structured clinical triage by Salud Responde nursing staff; and referral to primary care for definitive diagnosis and treatment. Implementation strategies include a structured EASP-accredited online training programme, ongoing technical support, activity feedback reports and a performance-based financial incentive of 20 euros per complete valid case.

    Also known as: Numaplus digital platform, Salud Responde CES 061, Kardias 6-lead portable ECG device

06

What researchers measure

Primary outcomes

  1. Implementation Adherence Grade (IAG)

    Implementation Adherence Grade (IAG) Composite fidelity index expressed as the percentage of mandatory protocol items completed per screening case, calculated as (number of mandatory items completed / 5) × 100. The five mandatory items, each scored dichotomously as completed (1) or not completed (0) and weighted equally, are: (1) written informed consent obtained and documented; (2) minimum demographic data recorded; (3) complete CHA₂DS₂-VA score calculated; (4) successful 30-second ECG tracing obtained within a maximum of three attempts; and (5) documented contact with Salud Responde for all cases classified as suspected or indeterminate atrial fibrillation. The pharmacy-level and study-level IAG is the mean of individual case-level IAG values. Target value: ≥90%. Unit of Measure: Percentage of mandatory protocol items completed (single composite index).

    Time frame: Through study completion, an average of 6 months

Secondary outcomes

  1. Participation rate (Reach)

    Proportion of patients aged 65 years or older who accept screening divided by the monthly denominator of unique patients aged 65 years or older attending each pharmacy.

    Time frame: Monthly, through study completion, an average of 6 months

  2. Pharmacy-level adoption rate

    Number of pharmacies completing at least one valid screening divided by the number of invited pharmacies.

    Time frame: At end of recruitment period (month 6)

  3. Acceptability of Intervention Measure (AIM) score

    Mean score of the 4-item AIM scale (range 1-5) measuring pharmacist acceptability of the screening programme.

    Time frame: At end of recruitment period (month 6)

  4. Feasibility of Intervention Measure (FIM) score

    Mean score of the 4-item FIM scale (range 1-5) measuring pharmacist-perceived feasibility of the screening programme.

    Time frame: At end of recruitment period (month 6)

  5. Suspected AF detection rate.

    Proportion of screened participants with Suspected AF classification by the Kardias device algorithm.

    Time frame: Through study completion, an average of 6 months

  6. Confirmed AF diagnosis rate.

    Proportion of screened participants with confirmed AF diagnosis following primary care assessment.

    Time frame: Through study completion, an average of 6 months

  7. Linkage to Care rate

    Proportion of participants with suspected or indeterminate AF who attend primary care appointment within the planned timeframe.

    Time frame: Up to 72 hours after positive or indeterminate screening result

  8. Oral anticoagulation initiation rate

    proportion of participants with confirmed AF initiated on oral anticoagulation.

    Time frame: Up to 6 months after confirmed AF diagnosis

  9. Major adverse events at 6 months

    Incidence of ischaemic stroke, major bleeding and death among participants with confirmed AF at 6-month follow-up.

    Time frame: 6 months after confirmed AF diagnosis

  10. Refusal rate and reasons

    proportion of eligible patients who decline screening, with the main reason for refusal recorded anonymously.

    Time frame: Monthly, through study completion, an average of 6 months

  11. Programme sustainability intention

    Proportion of pharmacists reporting intention to continue the screening programme beyond project funding period, assessed through the sustainability block of the post-study questionnaire.

    Time frame: At end of recruitment period (month 6)

  12. Salud Responde coordination performance

    Operational indicators of the Salud Responde (CES 061) triage node, including median time from ECG transmission to clinical validation, distribution of triage decisions (emergency 061 activation, medium priority referral, low priority referral), and qualitative assessment of circuit barriers by the SR coordination team at end of study.

    Time frame: Through study completion, an average of 6 months

  13. 13a. Salud Responde Coordination. ECG transmission.

    Median time from ECG transmission to Salud Responde clinical validation (minutes)

    Time frame: Through study completion, an average of 6 months

  14. Salud Responde coordination. Triage decission

    Distribution of Salud Responde triage decisions (percentage of cases in each category: emergency 061 activation / medium priority / low priority)

    Time frame: Through study completion, an average of 6 months

  15. SR circuit barrers

    Qualitative assessment of circuit barriers by Salud Responde coordination team (thematic categories)

    Time frame: At end of study (month 6)

07

Study locations

1 site
08

References and documents

Publications

  • Pinnock H, Barwick M, Carpenter CR, Eldridge S, Grandes G, Griffiths CJ, Rycroft-Malone J, Meissner P, Murray E, Patel A, Sheikh A, Taylor SJ; StaRI Group. Standards for Reporting Implementation Studies (StaRI) Statement. BMJ. 2017 Mar 6;356:i6795. doi: 10.1136/bmj.i6795. PubMed 28264797 ↗
  • Wahab A, Nadarajah R, Larvin H, Farooq M, Raveendra K, Haris M, Nadeem U, Joseph T, Bhatty A, Wilkinson C, Khunti K, Vedanthan R, Camm AJ, Svennberg E, Lip GY, Freedman B, Wu J, Gale CP. Systematic screening for atrial fibrillation with non-invasive devices: a systematic review and meta-analysis. Lancet Reg Health Eur. 2025 Apr 11;53:101298. doi: 10.1016/j.lanepe.2025.101298. eCollection 2025 Jun. PubMed 40276326 ↗
  • Van Gelder IC, Rienstra M, Bunting KV, Casado-Arroyo R, Caso V, Crijns HJGM, De Potter TJR, Dwight J, Guasti L, Hanke T, Jaarsma T, Lettino M, Lochen ML, Lumbers RT, Maesen B, Molgaard I, Rosano GMC, Sanders P, Schnabel RB, Suwalski P, Svennberg E, Tamargo J, Tica O, Traykov V, Tzeis S, Kotecha D; ESC Scientific Document Group. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024 Sep 29;45(36):3314-3414. doi: 10.1093/eurheartj/ehae176. No abstract available. PubMed 39210723 ↗
  • Glasgow RE, Vogt TM, Boles SM. Evaluating the public health impact of health promotion interventions: the RE-AIM framework. Am J Public Health. 1999 Sep;89(9):1322-7. doi: 10.2105/ajph.89.9.1322. PubMed 10474547 ↗
  • Curran GM, Bauer M, Mittman B, Pyne JM, Stetler C. Effectiveness-implementation hybrid designs: combining elements of clinical effectiveness and implementation research to enhance public health impact. Med Care. 2012 Mar;50(3):217-26. doi: 10.1097/MLR.0b013e3182408812. PubMed 22310560 ↗

Individual participant data

Plan to share: No — Individual participant data are pseudonymised and collected within the Andalusian Public Health System (SSPA). Data are subject to Spanish data protection legislation (Organic Law 3/2018, LOPD-GDD) and EU GDPR 2016/679 and cannot be made publicly available. Anonymised aggregate data supporting the conclusions of this study may be available upon reasonable request to the corresponding author, subject to institutional approval by the Centro de Emergencias Sanitarias 061 and the Comite Coordinador de Etica de la Investigacion Biomedica de Andalucia (CCEIBA).

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for Dec 2026, 6 months later.

Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 6 months is below that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2026
First posted
May 20, 2026
StartEst.
Jun 1, 2026
Primary completionEst.
Dec 15, 2026
CompletionEst.
Dec 31, 2026
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07598903
Lead sponsor
Centro de Emergencias Sanitarias 061 Andalucía
Collaborators
Andaluz Health Service, University of Seville, Real e Ilustre Colegio Oficial de Farmacéuticos de Sevilla, Andalusian School of Public Health, Andalusian Regional Ministry of Health
Responsible party
Sponsor
First posted
May 20, 2026
Start date
Jun 1, 2026 (estimated)
Primary completion
Dec 15, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
May 22, 2026

Study contacts

María José ML Luque-Hernández, MD, PhD
Contact
mariajose.luque.sspa@juntadeandalucia.es
+34683511613
Jesús Antonio JC Carrillo-Castrillo, PhD
Contact
jesus.carrillo.castrillo@juntadeandalucia.es
+34 955006300

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion